Physician profile
Paul Rushing
NPI 1003810904
$12,588.78
in general payments reported to CMS, 2019-2025
47 companies · $1,802 in 2025
The $1,802 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,135 · 2020: $1,498 · 2021: $1,925 · 2022: $2,003 · 2023: $1,493 · 2024: $1,733 · 2025: $1,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,028.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,802.18 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,680.51 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $920.66 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $846.66 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $776.87 | 2019-2025 | |
| Abbvie INC. | $742.20 | 2019-2025 | Qulipta, Ubrelvy, Linzess |
| Glaxosmithkline, LLC. | $665.07 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $651.58 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $628.93 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $547.23 | 2019-2025 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $382.06 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $247.63 | 2021-2025 | |
| Amarin Pharma, INC. | $229.68 | 2019-2022 | |
| Abbott Laboratories | $197.46 | 2021-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $194.30 | 2021-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Rushing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.